Flagship Pioneering-founded Valo Health has announced the appointment of Dr Brian Alexander as its new CEO.

Additionally, Alexander will serve as Flagship Pioneering’s CEO-partner.

With 20 years of experience in biotechnology and medical leadership, he aims to enhance Valo Health's mission to accelerate drug discovery and development.

Alexan­der said: “I am deeply honoured to join Flag­ship Pio­neer­ing and Valo Health at such a piv­otal time for the com­pa­ny. 

​“Our mis­sion at Valo is to accel­er­ate the dis­cov­ery and devel­op­ment of bet­ter medicines for patients by fun­da­men­tal­ly chang­ing the tra­di­tion­al dis­cov­ery par­a­digm, and I am excit­ed to lead and work with the amaz­ing tal­ent at Valo to deliv­er mean­ing­ful advance­ments for patients using the pow­er of AI and human-cen­tric data.”

His previous roles include CEO of Foundation Medicine and senior vice-president of research and development and head of Boston Roche Innovation Center for Roche/Genentech.

At Foundation Medicine, Alexander utilised molecular information to enhance cancer care and clinical decision-making.

Meanwhile, he focused on clinical development at Roche/Genentech, with machine learning, data science, and AI utilisation.

Earlier, he co-founded the Global Coalition for Adaptive Research to expedite treatment discovery and development for rare diseases through clinical trials.

Alexander was also the Harvard/MIT Center for Regulatory Science's founding director.

At Harvard Medical School, he served as an associate professor and was a radiation oncologist at the Dana-Farber Cancer Institute and Brigham and Women's Hospital.

Valo and Flag­ship Pio­neer­ing gen­er­al part­ner and exec­u­tive chair Paul Bion­di said: “I am delight­ed to wel­come Bri­an Alexan­der as the CEO of Valo Health and a Flag­ship Pio­neer­ing CEO-part­ner. 

​“Brian’s proven lead­er­ship across biotech­nol­o­gy makes him well-posi­tioned to guide Valo into its next chap­ter of growth, as it har­ness­es AI-dri­ven tech­nol­o­gy and high-qual­i­ty patient data to dis­cov­er and devel­op life-chang­ing medicines.”